Relativity Shareholders Approve Merger with Instinct Bio Technical

On March 24, 2026, shareholders of Relativity Acquisition Corp.

(OTC: ACQC) officially voted to approve a business combination with the Japanese firm Instinct Bio Technical Company Inc.

This merger, valued at approximately $242 million, allows the regenerative medicine company to go public and transition its shares to the NASDAQ exchange under the ticker symbol "BIOT."

Founded in 2017, Instinct Bio Technical distinguishes itself through a vertically integrated business model that controls the entire lifecycle of its stem cell-based skincare and wellness products.

Tomoki Nagano, the founder of the company, will lead the combined entity as it aims for international expansion.

The firm plans to use the capital raised from this public listing to scale its operations, including building new facilities in Japan and introducing its unique clinic model into markets like Malaysia and Indonesia.

While the merger is expected to close in the coming weeks, the successful shareholder vote signifies a major step toward the company's goal of becoming a global leader in the stem cell industry.